Anti-VEGF injections in Bhutan

# Profile of patients treated with intravitreal anti-vascular endothelial growth factor injections in Bhutan: a 3-year national survey

Bhim B. Rai<sup>1,2</sup>, Deepa Rai<sup>3</sup>, Ted Maddess<sup>1</sup>

<sup>1</sup>John Curtin School of Medical Research, Australian National University, Canberra, ACT, Australia.

<sup>2</sup>Department of Ophthalmology, JDW National Referral Hospital, Thimphu, Bhutan.

<sup>3</sup>Warrigal Aged Care Facility, Calwell, ACT, Australia.

# **Corresponding Author**

Dr. Bhim Bahadur Rai Building 131, Garran Road, John Curtin School of Medical Research, Australian National University, Canberra, ACT 2601. Email: bhim.rai@anu.edu.au Phone number: +61 2 61259253

AUTHOR ORCID IDs: Rai 0000 0003 0748 4581, Maddess 0000-0003-4591-3658.

AUTHOR EMAIL:

Bhim Rai: bhim.rai@anu.edu.au Deepa Rai: nana.raee@yahoo.com Ted Maddess: ted.maddess@anu.edu.au

Running title: Anti-VEGF injections in Bhutan

Words: 2,868

Figures: Nil

Tables: 2

#### ABSTRACT (285 WORDS)

Purpose: Ocular vascular diseases are common causes of visual impairment and blindness,
 for which intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) is the
 first-line therapy. Current study describes the profile of patients receiving intravitreal anti VEGF injections in Bhutan. This is the first study of its kind to inform the national health
 policy.

Methods: For this retrospective study, we reviewed the surgical registers of the vitreoretinal
unit across Bhutan over three years. Patient demography, clinical findings, diagnostic tests
performed, and diagnoses or indications for intravitreal anti-VEGF injections were logged. A
descriptive analysis was performed.

10 Results: A total of 381 patients received intravitreal anti-VEGF injections in the operating

11 theatres as mandated by the national guidelines. The majority of patients were males (230,

12 60.4%). The mean age was  $65.2 \pm 13.5$  years, ranging from 13 to 90 years, and a median of

13 69 years. Majority of the treated eyes (117, 30.7%) had BCVA <3/60 to light perception

14 (PL), and another 51 eyes (13.4%) had < 6/60 to 3/60. The most common indication for anti-

15 VEGF injection was neovascular AMD (168 cases, 42.2%), followed by retinal vein

16 occlusion (132 cases, 34.6%), diabetic macular oedema and retinopathy (50 cases, 13.1%),

17 and myopic choroidal neovascular membrane (11 cases, 0.03%).

18 Conclusions: Bhutan faces both economic and geographic challenges, on top of limited 19 human resources for managing vitreoretinal diseases. With an ever-increasing load of 20 vitreoretinal diseases, and systemic diseases like diabetes and hypertension, there is a need to 21 improve vitreoretinal services. Regular vitreoretinal services are provided only at the national 22 referral hospital located in the north-west. For successful management, an effective

Anti-VEGF injections in Bhutan

- 23 community screening program, right referrals, and proper transport facilities must go hand-
- 24 in-hand, and or extend regular vitreoretinal services to regional referral hospitals.
- 25 Key words: Anti-VEGF; Bhutan retinal diseases, diabetic macular oedema; intravitreal
- 26 injection; neovascular AMD; retinal vein occlusion.

medRxiv preprint doi: https://doi.org/10.1101/2022.12.01.22283009; this version posted December 5, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in percentitiv

perpetuity. It is made available under a CC-BY 4.0 International license . Anti-VEGF injections in Bhutan

#### 28 INTRODUCTION

29 Vascular diseases such as neovascular age-related macular degeneration (nAMD), diabetic 30 macular oedema (DMO) and diabetic retinopathy (DR), and retinal vein occlusion (RVO) are 31 the major causes of visual impairment and loss of central vision throughout the world (1). 32 Previously refractory cases were treated with intravitreal injection of corticosteroid 33 triamcinolone acetonide and dexamethasone (2). However, these agents were associated with 34 multiple ocular side effects such as cataract and intraocular pressure spikes (2). The 35 pathogeneses of many such diseases are multifactorial. Both inflammatory mediators and 36 vasogenic mediators, such as vascular endothelial growth factors (VEGFs), are activated and 37 create disruption of the retina (3, 4). As the inner blood-retinal barrier breaks down, fluids 38 and proteins leak into the retina. This leakage creates oedema of the macula and thereby 39 decreases the retinal transparency (2-5). To counter this effect, anti-VEGFs came into clinical 40 use with much promise. It also earned the name of a one day wonder drug for the fast 41 resolution of DMO following intravitreal injection of ranibizumab (6). Among anti-VEGFs, 42 bevacizumab (AVASTIN, Genentech, Inc.,) was the first agent to be used off-label in 2005. 43 Subsequently, multiple anti-VEGF agents such as pegaptanib sodium (Eyestech/OSI Pharmaceuticals, New York, NY, USA), ranibizumab (Lucentis<sup>™</sup>, Genentech, Inc., South 44 45 San Francisco, CA, USA and Novartis Pharma AG, Basel, Switzerland), aflibercept (VEGFtrap eve, Eylea<sup>™</sup>, Regeneron Pharmaceuticals, Inc., and Bayer Pharma AG, Berlin, 46 47 Germany), brolucizumab (Beovu<sup>™</sup>, Novartis Pharma AG, Basel, Switzerland), and faricimab 48 have been developed for the management of various ocular vascular diseases (7-11). 49 Although all these agents are used, only pegabtanib, ranibizumab, brolucizumab, aflibercept, 50 and faricimab are approved for use in ophthalmological disorders (11-13). Ranibizumab, 51 bevacizumab and brolucizumab specifically target VEGF-A activity, while aflibercept has a broader spectrum of action - VEGF-A, as well as other VEGF family ligands such as VEGF-52

perpetuity. It is made available under a CC-BY 4.0 International license . Anti-VEGF injections in Bhutan

53 B, placental growth factor-1 (PIGF-1) and placental growth factor-2 (PIGF-2) (14, 15). 54 Faricimab is a new and the first bispecific monoclonal antibody for intravitreal use 55 neutralising both VEGF and angiopoietin-2/tie-2/ pathway(16). Due to the prolonged activity, 56 faricimab allows extended intervals between injections of up to three or four months in 57 nAMD and DMO patients, which can be a significant benefit for patients and are an 58 alternative to implanted drug delivery systems (17, 18). The aim of the current study was to report on the profile of patients treated with intravitreal anti-VEGFs injections for 59 60 ophthalmological diseases in Bhutan. Since this is the first study of this kind in the country 61 and the results have impacts for policy making in Bhutan and other developing countries in the region. 62

#### 63 METHODS

#### 64 Study design and Ethics

This was a retrospective, case series study approved by the Research Ethics Board of Health
(REBH) (REBH/Approval/2016/083), Ministry of Health, Royal Government of Bhutan,
Thimphu, Bhutan. This study adhered to the principles of the Declaration of Helsinki.
Informed consent was waived by REBH because this retrospective study collected only deidentified data.

#### 70 Setting

71 In Bhutan the Jigme Dorji Wangchuck (JDW) national referral hospital is the only apex

national referral and teaching hospital with subspecialty eye-care services. Regular

vitreoretinal surgical and interventional services in the country are provided only at the JDW

national referral hospital. All such vitreoretinal patients across the country are referred there

75 for management. Occasionally the vitreoretinal surgeon visits Eastern Regional Referral

76 Hospital (ERRH) in Mongar and Central Regional Referral Hospital (CRRH) in Gelephu

Anti-VEGF injections in Bhutan

when the treatment is provided there. The sites for the current study included JDW national
referral hospital (in the main), and ERRH and CRRH.

#### 79 **Participants**

80 All the patients who received intravitreal anti-VEGF injections in the operation theatres at the

JDW national referral hospital, ERRH and CRRH over three years (01 May 2013 until 30

82 April 2016) were included. The national guidelines mandate that intravitreal injections should

83 be administered only in operating theatres with proper aseptic measures. The demographic

84 characteristics of patients receiving the anti-VEGF injection and the vitreoretinal disease

85 pattern represent the entire citizenry.

# 86 Clinical Examination and data collection

87 The clinical workup in the out-patient department (OPD) included taking detailed medical histories of presenting symptoms and diseases, associated systemic diseases, and prior 88 89 surgical or laser interventions done. Best corrected visual acuity (BCVA) at presentation was 90 measured using a Snellen chart, and Tumbling E for illiterate patients. Intraocular pressure 91 was measured by Goldmann applanation tonometry or an iCare tonometer, and the anterior 92 and posterior segments were examined under slit-lamp biomicroscopy (BM 900, Haag-Streit, 93 Switzerland) and 90D bio-microscopy. The funduscopic findings were confirmed by 94 binocular indirect ophthalmoscope (Model 125, Welch Allyn, USA). Macular and retinal 95 nerve fibre (RNFL) scans were measured using a Spectral Domain Optical Coherence 96 Tomography (OCT) (Cirrus-HD 4000, Carl Zeiss Germany). Fundus photographs were taken 97 by a VISUCAM-524 (Carl Zeiss, Germany). Fundus fluorescein angiograms (FFA) were 98 performed when needed to confirm occult diseases. A B-ultra sonogram scan was done when 99 necessary (Sonomed Escalon, Model: VUPAD A/B, USA).

It is made available under a CC-BY 4.0 International license Anti-VEGF injections in Bhutan

For the current study, the patient register maintained in the vitreoretinal operational theatre
was reviewed for the data collection. The data collected included demographic information
such as age and gender, residential settings, BCVA, diagnostic tests performed, and diagnosis
or indications for anti-VEGF injections.

### 104 **Diagnostic tests**

- 105 OCT was performed universally on all cases who have received intravitreal anti-VEGF
- 106 injections. This was an appropriate diagnostic tool to diagnose nAMD, RVO, DMO, myopic
- 107 choroidal neovascular membrane (mCNVM), cystoid macular oedema, central serous
- 108 chorioretinopathy and vitreomacular tractions. Polypoidal choroidal vasculopathy (PCV) is
- 109 best diagnosed via its characteristic nodular dilatations arising from neovascular networks
- 110 that ramify mainly in the subretinal pigment epithelial space on indocyanine green
- 111 angiography.(19, 20) However, in the current study the PCV was mainly diagnosed based on
- 112 the OCT findings such as sharp-peaked retinal pigment epithelial detachment (RPED),
- subretinal pigment detachment ring-like lesion, multilobular RPED, double-layer sign or
- shallow, irregular retinal pigment epithelium elevation, thick choroid with dilated Haller's
- 115 layer vessels, and predominance of subretinal fluid. Other suggestive findings with the
- 116 coloured fundus photographs were extensive subretinal haemorrhage, and orange
- 117 nodules.(21) The FFA was performed only in difficult or occult cases.

# 118 Anti-VEGF injections

Most of the time, a 4 ml vial containing 100 mg bevacizumab was procured. The patients needing intravitreal anti-VEGF injections were pooled for a scheduled injection day, when a vial was opened and dosing formulation done at 1.25 mg per 0.05 ml, or 2.5 mg per 0.1 ml in tuberculin syringes with 30G needles. So a single vial would benefit 20 to 25 pooled patients. This approach was practised for economic reasons. The anti-VEGF dosing formulations and intravitreal injections were performed under aseptic measures in the operating theatres.

Anti-VEGF injections in Bhutan

- 125 Injections into the bilateral eyes in the same siting was not performed to avoid complications,
- 126 notably endophthalmitis.

127 RESULTS

#### 128 **Demographic characteristics**

- 129 A total of 381 patients received intravitreal anti-VEGF injections over the study period. The
- 130 majority of patients (230, 60.4%) were males, and others females (151, 39.6%). The mean
- 131 age at presentation was  $65.2 \pm 13.5$  years (ranging from 13 to 90 years), modal year of 70
- 132 years, and median 69 years.

# 133 Visual acuity

- 134 BCVA at presentation was recorded in the vitreoretinal unit OPD register and the patient
- 135 personal files. For the current study we referred to the surgical register maintained in the
- 136 operating theatre, where BCVA for all cases were not recorded. As a result, the data on
- 137 BCVA was not available (NA) in 85 cases (Table 1). Among those with BCVA data
- 138 available, majority of the eyes treated with anti-VEGF injections had BCVA of less than 3/60
- to only perception of light (PL), labelled as blindness according to World Health
- 140 Organisation (WHO) classification of visual impairment, in the treated eyes (117 cases, 30.7)
- 141 (22). We could not ascertain if they were legally blind with this because we did not have the
- 142 data on BCVA of their fellow eyes. The details of the BCVA are shown in **Table 1**.
- 143

Table 1. Best corrected visual acuity at presentation

Visual acuity based on WHO classification of blindness	No. of eyes	Percentage
$\geq 6/18$	21	5.5
< 6/18 - 6/60	107	28.1
< 6/60 - 3/60	51	13.4
< 3/60 - PL*	117	30.7
NA†	85	22.3
NPL^	0	0

Anti-VEGF injections in Bhutan

144

*Total* 381 100

NA<sup>†</sup>: Data not available; NPL<sup>^</sup>: No perception of light; PL<sup>\*</sup>: Perception of light.

# 145 Intravitreal anti-VEGF injections

- 146 nAMD was the most common indication for the intravitreal anti-VEGF injection, accounted
- 147 for 168 cases (44.2%). This was followed by RVO in 132 cases (34.6%). Within the RVO
- subgroup, branch RVO (BRVO) was the most common subgroup with 70 cases (53.0%),
- 149 followed by central RVO (CRVO) in 55 cases (41.7%), and hemi-retinal BRVO (HRBRVO)
- 150 in 7 cases (5.3%). Only 50 cases (13.1%) receiving anti-VEGF injections had DR or DMO,
- 151 11 cases (0.03%) had mCNVM, and 6 cases (0.02%) had PCV. Other indications for anti-
- 152 VEGF injections are shown in **Table 2**.

# 153 Table 2: Indications of anti-VEGF Injection

Indications	Number of cases	Percentage
Neovascular AMD	168	44.2
Total Retinal Vein Occlusion	132	34.6
Branch Retinal Vein Occlusion (BRVO)	70	53.0
Central Retinal Vein Occlusion (CRVO)	55	41.7
Hemi-retinal BRVO (HRBRVO)	7	5.3
Diabetic Macular Oedema	50	13.1
Myopic CNVM (mCNVM)	11	0.03
Polypoidal Choroidal Vasculopathy (PCV)	6	0.02
Neovascular Glaucoma	4	0.01
Others*	10	0.03
Total	381	100.0

154 2 cases of injection were excluded as the indications were not recorded.

155 \*Others include Cystoid macular oedema, Central serous chorioretinopathy and Vitreomacular traction

### 156 DISCUSSION

157 To summarise the vital results, 30.7% of the study eyes were legally blind, 13.4% had severe

158 visual impairment (VI) and 28.1% has moderate VI as per the WHO classification of VI (22).

It is made available under a CC-BY 4.0 International licen Anti-VEGF injections in Bhutan

nAMD was the most common indication for intravitreal anti-VEGF injections, followed by
RVO, DMO/DR, mCNVM, PCV, and neovascular glaucoma.

161 A study on the pattern and presentation of vitreoretinal diseases in Bhutan in the same period 162 reported that majority of patients were males, 1544/2913 (23). That is somewhat lower than 163 the rate seen here (p=0.048,  $\chi^2$ =3.90). A meta-analysis of eye surgical services in developing countries has shown that females receive fewer surgical or interventional services than the 164 165 males (24), as was seen with receiving anti-VEGF injections in the current study. The 166 national vitreoretinal unit was established in Bhutan only in early 2012 (25), Prior to that, vitreoretinal cases were referred to India or Nepal for treatment. Most patients were reluctant 167 168 to go out of the country for surgery, however, because of the communication gap in foreign 169 lands. This partly encouraged some patients to seek to traditional or indigenous methods of 170 healing. Some even sought to local healers or witchcraft practice with false hope, resulting in 171 irreversible loss of vision and even loss of eyes, while most cases did not receive any treatment and accepted it as their destiny. 172

173 AMD was reported as the fourth most common vitreoretinal disease in Bhutan, next to 174 hypertensive retinopathy, refractive errors referred for retinal evaluation, and DR or clinically 175 significant macular oedema (CSMO) (23). So it is apparent that intravitreal anti-VEGF 176 injection was most commonly administered to nAMD cases. Another study on the profile of 177 AMD in Bhutan reported that half of AMD cases were in advance stages needing treatment, 178 and one-third of those with advanced diseases already had disciform scar at their first 179 presentation (26). Similarly, the drop-out rates for follow-up are high. The reason for such 180 late presentation and poor follow-up or medical adherence are many. First, lack of knowledge 181 of the general public on diseases and treatment options available. Secondly, lack of 182 accessibility to services – the regular vitreoretinal service is provided only at the JDW 183 national referral hospital located in the north-west part of the country and the patients from

It is made available under a CC-BY 4.0 International license Anti-VEGF injections in Bhutan

184 the central and eastern regions have to travel all the way against difficult terrain, poor road 185 conditions and transport limitations to avail the treatment. Other reasons include poor referral 186 system, communication gap between the peripheral and referral hospitals, and negative 187 influence of the local healers. 188 Co-existent hypertension and diabetes mellitus, the complications of which result to many 189 ocular vascular diseases, is common in Bhutan (27). WHO has reported that 28% of total 190 mortality in Bhutan was due to cardiovascular disease, and another 17% due to other non-191 communicable diseases (28). For these morbidities, the risk factors include harmful use of 192 alcohol, high salt intake, unhealthy diet, physical inactivity, and tobacco use (29). 193 Considering hypertensive retinopathy and diabetes mellitus as risk factors for RVO (30), and 194 both being common among the Bhutanese population, RVO cases received the second highest number of anti-VEGF injections. Similarly, RVO cases also was the second most 195 196 common indication to receive retinal laser therapy in the country, second only to DR/DMO 197 (31). Only 50 cases (13.1% of all anti-VEGF injections) received anti-VEGF injection in the study population although DR and DMO was the third most common vitreoretinal disease in 198 199 Bhutan, and second most common in a similar study conducted in Nepal (32). This is because 200 only the central DMO, and DMO nasal to the fovea, were treated with anti-VEGF injection. 201 Very severe DR not responding to panretinal photocoagulation (PRP) were also first treated 202 with the anti-VEGF injections to reduce retinal oedema after which PRP was performed 203 successfully. Commonly, the DR cases were managed with PRP to such a rate that PRP was 204 the most common type of retinal laser therapy performed in Bhutan (31). Off-centre DMO 205 (except DMO nasal to the fovea) was managed with focal, grid or modified grid laser 206 therapies. An unpublished study (under review with the Japanese J of Ophthalmology) has 207 reported that 25.6% of diabetes patients presented 5-10 years after diagnosis, 19.9% after 10-208 20 years and 2.3% presented only after 20 years for the first time for their eye/retinal check-

medRxiv preprint doi: https://doi.org/10.1101/2022.12.01.22283009; this version posted December 5, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

perpetuity. It is made available under a CC-BY 4.0 International license . Anti-VEGF injections in Bhutan

209 up. The study also reported that 12.5% of DR cases had proliferative DR at their first210 presentation for retinal evaluation.

211 Although the moderate to high myopic cases referred for retinal evaluation was the second 212 most common reason for attending vitreoretinal clinics in Bhutan, next to hypertensive 213 retinopathy (23), only a small percentage of anti-VEGF injections was given to cases of 214 myopic CNVM (mCNVM). This is because the prevalence of mCNVM among the study 215 group of myopia was only 0.4% (33). Other studies have reported that mCNVM occurs in 216 approximately 5-10% of highly myopic patients, and 0.04-0.05% of the general population (34, 35). PCV is common chorioretinal disorder among the Asian populations.(36) It has been 217 218 estimated that up to 50% of nAMD cases among the Asians are of the PCV subtype, whereas 219 this proportion among the white populations is estimated to range between 10% and 20% (37, 220 38). In Bhutan, 8.1% of advanced AMD were comprised of PCV, and among them 73.7% of 221 them (14/19 cases) were younger than 50 years (26). This is highly concerning for a country 222 like Bhutan with a small reserve of working age population and limited human resources. Yet 223 only six of nineteen cases of PCV received anti-VEGF treatment, that is, 68.4% of them did 224 not receive treatment. There is fear that they may turn up later with worsened disease not 225 being amenable to the treatment. With these concerns, it was also deliberated that community 226 screening of AMD along with PCV cases might be helpful in Bhutan (39). However, until 227 today, it seems there are no large-scale screening programs for AMD like those that exist for 228 DR and retinopathy of prematurity.

It is common that younger patients have poor medical adherence (40). So the treating physicians and the healthcare professionals have to give extra effort to teach them about the disease and ensure the importance of timely medications. Additionally, the general population in Bhutan are illiterate and have poor knowledge of diseases and treatment options. Although health education is provided at all levels of healthcare centres in Bhutan

perpetuity. It is made available under a CC-BY 4.0 International license . Anti-VEGF injections in Bhutan

234 there is need to improve the program. It may be effective to disseminate health advocacy 235 information in the local languages or dialects so the common people are able to understand 236 the message. Involving local leaders and local government bodies may prove more effective. 237 Broadcasting the materials through the national television channels, or even targeting the 238 younger generations through the mobile phone applications they use, may be helpful. For 239 regionally balanced delivery of the services, Bhutan needs to extend its regular vitreoretinal 240 services to the ERRH and CRRH, or at least improve community screening and effective 241 referral system. New approaches to screening and management of the AMD cases may allow 242 for expansion of high-quality convenient care and increasing patient coverage (41). The 243 public transport system in Bhutan is challenged by difficult terrain, poor quality of roads and 244 infrequent services. Additionally, it is interrupted during monsoon season by landslides, 245 falling boulders and swollen rivers and streams, and by snowfall during winters. Therefore, 246 the proper arrangement of transport facilities for the patients is a must for successful 247 screening and referral program. For referrals too, a concept of *right referral* must be 248 practised. Only the patients needing to be seen by the retinal specialist and interventions at 249 the national referral hospital should be referred. If patients are referred only to be told that no 250 further action required after taking a difficult journey, then such improper referral will 251 certainly have negative impact on the program. Tactfully, Bhutan also needs to lower the 252 influence of local healers and encourage people to visit hospitals while having health issues. 253 Although Bhutan still struggles to provide basic medical provision and low-cost treatment, it 254 may be worth to identify patients who are not compliant to follow up or adherent to 255 medication and provide longer acting anti-VEGF treatment such as faricimab, which can 256 extend the intervals between successive drug administration by 4 to 6 months (17, 18). 257 This study is limited by being a retrospective study and a small number of study subjects.

258 We did not have visual acuity at presentation for 85 cases (22.3%). Being a cross-sectional

Anti-VEGF injections in Bhutan

study, we also did not follow up the patients to understand the outcome of the anti-VEGF
treatment. We have a plan to conduct a prospective study overcoming all the limitations of
the current study.

#### 262 CONCLUSIONS

263 There is need to improve the vitreoretinal services in Bhutan. Currently regular vitreoretinal

service is provided only at the JDW national referral hospital, so there is high risk that the

265 patients from the eastern and central regions miss out on the treatment and regular follow up.

266 So regular services need to be expanded to the eastern and central regional referral hospitals.

267 Secondly, vitreoretinal diseases secondary to systemic diseases such as hypertension and

268 diabetes are common. There is an urgent need for strategic control and management of non-

269 communicable diseases and prevent blindness and visual impairment from their

270 complications.

# 271 DECLARATIONS

# 272 **Conflict of interest**

Author BBR declares that he has no conflict of interest. Author DR declares that she has noconflict of interest. Author TM declares that he has no conflict of interest.

# 275 Funding

The funders had no role in study design, data collection and analysis, decision to publish, orpreparation of the manuscript.

Anti-VEGF injections in Bhutan

#### 278 Ethical approval, Informed Consent and Consent for Publication

- 279 The study was approved by the Research Ethics Board of Health (REBH)
- 280 (REBH/Approval/2016/083), Ministry of Health, Royal Government of Bhutan, and was
- 281 conducted as per the REBH guidelines and tenets of the Declaration of Helsinki. The consent
- 282 was waived by REBH as the retrospective study collected only the de-identified data.

#### 283 Availability of data and material

284 The data and material are available with the corresponding author.

perpetuity. It is made available under a CC-BY 4.0 International license .

Anti-VEGF injections in Bhutan

# 286 REFERENCES

- Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global prevalence
   and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556-64.
- 289
   2. Stewart MW. Corticosteroid use for diabetic macular edema: old fad or new trend? Curr
   290
   Diab Rep. 2012;12(4):364-75.
- Noma H, Yasuda K, Shimura M. Cytokines and the Pathogenesis of Macular Edema in Branch
   Retinal Vein Occlusion. J Ophthalmol. 2019;2019:5185128.
- 2934.Nowak JZ. Age-related macular degeneration (AMD): pathogenesis and therapy. Pharmacol294Rep. 2006;58(3):353-63.
- 295 5. Duh EJ, Sun JK, Stitt AW. Diabetic retinopathy: current understanding, mechanisms, and
   296 treatment strategies. JCI Insight. 2017;2(14).
- 297 6. Verma L, Chakravarti A, Gupta A, Prakash S. One day wonder: fast resolution of macular
  298 edema following intravitreal ranibizumab in retinal venous occlusions. Indian J Ophthalmol.
  2013;61(9):528-30.
- Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, et al. Intravitreal
   aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology.
   2012;119(12):2537-48.
- 3038.Group CR, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, et al. Ranibizumab and304bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897-305908.
- Jonas J, Paques M, Mones J, Glacet-Bernard A. Retinal vein occlusions. Dev Ophthalmol.
   2010;47:111-35.
- 308 10. Wroblewski JJ, Wells JA, 3rd, Adamis AP, Buggage RR, Cunningham ET, Jr., Goldbaum M, et
  309 al. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Arch
  310 Ophthalmol. 2009;127(4):374-80.
- 311 11. Khoramnia R, Figueroa MS, Hattenbach LO, Pavesio CE, Anderesi M, Schmouder R, et al.
   312 Manifestations of intraocular inflammation over time in patients on brolucizumab for neovascular
- 313 AMD. Graefes Arch Clin Exp Ophthalmol. 2022;260(6):1843-56.
- Kaiser PK, Cruess AF, Bogaert P, Khunti K, Kelly SP. Balancing risk in ophthalmic prescribing:
   assessing the safety of anti-VEGF therapies and the risks associated with unlicensed medicines.
   Graefes Arch Clin Exp Ophthalmol. 2012;250(11):1563-71.
- 317 13. AJMC. FDA Approves Faricimab to Treat Wet AMD and DME USA: AJMC; 2022 [updated 1
   318 Fabruary 2022; cited 2022 07 November]. Available from: <a href="https://www.ajmc.com/view/fda-">https://www.ajmc.com/view/fda-</a>
- 310 Pabluary 2022, cited 2022 07 November J. Available from: <u>https://www.ajinc.co</u> 310 approves fariyimab to treat wet and and dme.
- 319 <u>approves-fariximab-to-treat-wet-amd-and-dme</u>.
- 32014.Sharma A, Kumar N, Kuppermann BD, Bandello F, Loewenstein A. Faricimab: expanding321horizon beyond VEGF. Eye (Lond). 2020;34(5):802-4.
- 15. Khanani AM, Guymer RH, Basu K, Boston H, Heier JS, Korobelnik J-F, et al. TENAYA and
   LUCERNE: Rationale and Design for the Phase 3 Clinical Trials of Faricimab for Neovascular Age Related Macular Degeneration. Ophthalmology Science. 2021;1(4):100076.
- 325 16. Nicolò M, Ferro Desideri L, Vagge A, Traverso CE. Faricimab: an investigational agent
   326 targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases. Expert
   327 Opin Investig Drugs. 2021;30(3):193-200.
- 328 17. Liberski S, Wichrowska M, Kocięcki J. Aflibercept versus Faricimab in the Treatment of
- Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review. Int J MolSci. 2022;23(16).

Anti-VEGF injections in Bhutan

331	18 Nair AA Einn AD Starnharg D. Ir. Spatlight on Earleimah in the Treatment of Wet Age.
222	Related Macular Degeneration: Decign, Development and Place in Therapy, Drug Dec Devel Ther
222	
222	2022;10:3395-400.
225	19. Yannuzzi LA, Sorenson J, Spalde RF, Lipson B. IDIOPATHIC POLYPOIDAL CHOROIDAL
222	VASCULOPATHY (IPCV). RETINA. 2012;32:1-8.
336	20. Spaide RF, Yannuzzi LA, Slakter JS, Sorenson J, Orlach DA. Indocyanine green
337	videoangiography of idiopathic polypoidal choroidal vasculopathy. Retina (Philadelphia, Pa).
338	1995;15(2):100-10.
339	21. Cheung CMG, Lai TYY, Teo K, Ruamviboonsuk P, Chen S-J, Kim JE, et al. Polypoidal Choroidal
340	Vasculopathy: Consensus Nomenclature and Non–Indocyanine Green Angiograph Diagnostic Criteria
341	from the Asia-Pacific Ocular Imaging Society PCV Workgroup. Ophthalmology. 2021;128(3):443-52.
342	22. Sivakumar P, Vedachalam R, Kannusamy V, Odayappan A, Venkatesh R, Dhoble P, et al.
343	Barriers in utilisation of low vision assistive products. Eye (Lond). 2020;34(2):344-51.
344	23. Rai BB, Morley MG, Bernstein PS, Maddess T. Pattern of vitreo-retinal diseases at the
345	national referral hospital in Bhutan: a retrospective, hospital-based study. BMC Ophthalmol.
346	2020;20(1).
347	24. Lewallen S, Courtright P. Gender and use of cataract surgical services in developing
348	countries. Bull World Health Organ. 2002;80(4):300-3.
349	25. TIO. Bhutan's Saviour. Bhutan News Service. 2012.
350	26. Rai BB, Morley MG, Bernstein PS, Maddess T. Severity of age-related macular degeneration
351	at first presentation in Bhutan: a 3-year national study. BMC Ophthalmol. 2022;22(1).
352	27. Giri BR, Sharma KP, Chapagai RN, Palzom D. Diabetes and hypertension in urban bhutanese
353	men and women. Indian J Community Med. 2013;38(3):138-43.
354	28. WHO. Non-communicable diseases: Country profile 2018 2018 [cited 2022 12 May ].
355	29. Pelzom D. Isaakidis P. Oo MM. Gurung MS. Yangchen P. Alarming prevalence and clustering
356	of modifiable noncommunicable disease risk factors among adults in Bhutan: a nationwide cross-
357	sectional community survey. BMC Public Health. 2017:17.
358	30. Kolar P. Risk factors for central and branch retinal vein occlusion: a meta-analysis of
359	published clinical data. J Ophthalmol. 2014:2014:724780.
360	31. Rai BB, Morley MG, Zangmo P, Tshering T, Khatiwara AN, Bernstein PS, et al. Retinal laser
361	services in Bhutan: a 3-year national survey, BMC Ophthalmol. 2020;20(1):404
362	32 Rai BB Shresthra MK Thana R Essex RW Paudval G Maddess T Pattern and presentation
363	of vitreo-retinal diseases an analysis of retrospective data at a tertiary eve care centre in Nenal Asia-
364	Pac   Onhthalmol 2019:8(6):481-8
365	33 Rai BB Ashby RS French AN Maddess T Rural-urban differences in myonia prevalence
366	among myones presenting to Bhutanese retinal clinical services: a 3-year national study. Graefes
367	Arch Clin Evn Onbthalmol. 2021:250(2):612-21
368	Arch Clin LXp Ophthalmol. 2021,239(3).013-21. 34 Avila MP Weiter II. Jalkh AF Trempe CL. Pruett RC Schenens CL. Natural history of
360	choroidal neovascularization in degenerative myonia. Onbthalmology 1081.01(12):1572-81
370	25 Erodotto ML Ciguero A Anderson DP Rudenz DL McSolov L Comparison of Matrix with
271	SS. Fredette MJ, Giguere A, Anderson DK, Budenz DE, McSoley J. Comparison of Matrix with Humphroy Field Applyzer II with SITA. Optom Vic Sci. 2015;02(5):527-26
271	Chaung CM, Vang E, Leo WK, Leo CK, Mathur D, Chang L, et al. The natural history of
272	36. Cheung Civi, Yang E, Lee WK, Lee GK, Mathur R, Cheng J, et al. The natural history of
272	Clip Sup Onbthe mel 2015-252(12):2075 85
5/4 275	Clin Exp Ophthalmol. 2015;253(12):2075-85.
3/3	37. Laude A, Cackett PD, Vithana EN, Yeo IY, Wong D, Kon AH, et al. Polypoidal choroidal
3/0	vasculopatny and neovascular age-related macular degeneration: Same or different disease?
3// 270	Progress in Retinal and Eye Research. 2010;29(1):19-29.
5/8	38. Loscas G, Yamashiro K, Loscas F, De Benedetto U, Isujikawa A, Miyake M, et al. Comparison
5/9	of Exudative Age-related Macular Degeneration Subtypes in Japanese and French Patients:
380	Nulticenter Diagnosis With Multimodal Imaging. American Journal of Ophthalmology.
381	2014;158(2):309-18.e2.

Anti-VEGF injections in Bhutan

- 382 39. Rai BB, Morley MG, Bernstein PS, Maddess T. Profile of age-related macular degeneration in
- 383 Bhutan: Should screening be considered? Investigative Ophthalmology & Visual Science.
- 384 2022;63(7):368 - F0199-368 - F.
- 385 40. Glombiewski JA, Nestoriuc Y, Rief W, Glaesmer H, Braehler E. Medication adherence in the 386 general population. PLoS One. 2012;7(12):e50537.
- 387 41. Brady CJ, Garg S. Telemedicine for Age-Related Macular Degeneration. Telemed J E Health. 388 2020;26(4):565-8.